Gujarat Themis Biosyn Ltd
₹371.95
(4.42%)
Sat, 17 Oct 2026, 11:42 am
Health Technology
Pharmaceuticals: Major
24.5KGujarat Themis Biosyn Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 4.71 | 10.65 | 3.13 | 11.99 | 15.93 | 17.23 | 15.68 | 8.91 | 5.96 | 9.80 | 13.57 | 86.01 | 48.64 | 62.89 |
| Price to book ratio | 2.34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.02 | 9.35 | 5.07 | 3.08 | 3.35 | 4.23 | 5.73 | 6.69 | 14.29 | 12.35 |
| Price to sales ratio | 0.93 | 1.01 | 0.48 | 0.52 | 0.99 | 0.65 | 0.89 | 0.40 | 0.47 | 1.75 | 2.26 | 2.12 | 1.56 | 1.39 | 1.66 | 3.27 | 5.15 | 33.60 | 16.94 | 20.34 |
| Price to cash flow ratio | 311.96 | 0 | 9.92 | 0 | 5.74 | 4.62 | 3.86 | 0 | 3.89 | 23.21 | 20.37 | 30.35 | 11.18 | 0 | 115.72 | 6.40 | 19.80 | 148.29 | 44.12 | 32.60 |
| Enterprise value | 28.35Cr | 27.05Cr | 22.43Cr | 22.43Cr | 28.9Cr | 21.58Cr | 18.28Cr | 22.47Cr | 22.09Cr | 60.91Cr | 76.94Cr | 78.92Cr | 56.71Cr | 61.06Cr | 147Cr | 260Cr | 581Cr | 4977Cr | 2864Cr | 3085Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 11.45 | 0 | 22.64 | 0 | 0 | 5.98 | 3.38 | 9.24 | 12.60 | 12.98 | 8.71 | 8.17 | 4.61 | 6.25 | 9.77 | 66.57 | 36.36 | 43.50 |
| Debt to equity ratio | 2.19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.90 | 0.50 | 0.05 | 0.32 | 0.19 | 0.07 | 0.01 | 0 | 0.01 | 0.12 |
| Return on equity % | 0 | -3810 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 337.22 | 74.57 | 38.90 | 42.06 | 77.99 | 53.82 | 50.35 | 45.92 | 33.76 | 21.69 |
Gujarat Themis Biosyn Ltd Ratios
The Gujarat Themis Biosyn Ltd Ratios page provides a complete fundamental analysis of Gujarat Themis Biosyn Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Gujarat Themis Biosyn Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Gujarat Themis Biosyn Ltd (NSE: GUJTHEM, BSE: 506879) is currently trading at ₹371.95, with a market capitalization of ₹5102.6Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Gujarat Themis Biosyn Ltd remains a key stock for fundamental analysis using Gujarat Themis Biosyn Ltd Ratios.
Gujarat Themis Biosyn Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Gujarat Themis Biosyn Ltd P/E ratio currently stands at 62.89, making it one of the most tracked metrics in Gujarat Themis Biosyn Ltd Ratios.
Historically, the Gujarat Themis Biosyn Ltd P/E ratio has shown strong fluctuations:
- 2024: 62.89
- 2023: 48.64
- 2022: 86.01
- 2021: 13.57
- 2020: 9.80
The rising Gujarat Themis Biosyn Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Gujarat Themis Biosyn Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 12.35.
Historical P/B trend:
- 2024: 12.35
- 2023: 14.29
- 2022: 6.69
- 2021: 5.73
Gujarat Themis Biosyn Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Gujarat Themis Biosyn Ltd P/S ratio currently stands at 20.34, an important part of Gujarat Themis Biosyn Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 20.34
- 2023: 16.94
- 2022: 33.60
- 2021: 5.15
The rising Gujarat Themis Biosyn Ltd P/S ratio indicates improved revenue valuation by investors.
Gujarat Themis Biosyn Ltd Price to Cash Flow Ratio (P/CF)
The Gujarat Themis Biosyn Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 32.60.
Historical Gujarat Themis Biosyn Ltd Price to Cash Flow Ratio:
- 2024: 32.60
- 2023: 44.12
- 2022: 148.29
- 2021: 19.80
- 2020: 6.40
The declining Gujarat Themis Biosyn Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Gujarat Themis Biosyn Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Gujarat Themis Biosyn Ltd EV currently stands at ₹3085Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 3085Cr
- 2023: 2864Cr
- 2022: 4977Cr
- 2021: 581Cr
Gujarat Themis Biosyn Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Gujarat Themis Biosyn Ltd EV/EBITDA ratio is currently 43.50, a key metric in Gujarat Themis Biosyn Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 43.50
- 2023: 36.36
- 2022: 66.57
- 2021: 9.77
Higher Gujarat Themis Biosyn Ltd EV/EBITDA suggests premium valuation.
Gujarat Themis Biosyn Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Gujarat Themis Biosyn Ltd D/E ratio is currently 0.12, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.12
- 2023: 0.01
- 2022: 0
- 2021: 0.01
Gujarat Themis Biosyn Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Gujarat Themis Biosyn Ltd ROE currently stands at 21.69%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 21.69
- 2023: 33.76
- 2022: 45.92
- 2021: 50.35
Gujarat Themis Biosyn Ltd demonstrates strong profitability and efficient capital utilization.
Gujarat Themis Biosyn Ltd Ratios Analysis Summary
The Gujarat Themis Biosyn Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Gujarat Themis Biosyn Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Gujarat Themis Biosyn Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
